Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a period of improvement (relapsed) or that has not responded to previous treatment (refractory). Mosunetuzumab and polatuzumab vedotin are monoclonal antibodies that may interfere with the ability of cancer cells to grow and spread. Polatuzumab, linked to a toxic agent called vedotin, attaches to CD79B positive cancer cells in a targeted way and delivers vedotin to kill them. Lenalidomide may stimulate or suppress the immune system in different ways and stop cancer cells from growing and by preventing the growth of new blood vessels that cancer cells need to grow. Giving mosunetuzumab with polatuzumab vedotin and lenalidomide may work better in treating patients with relapsed/refractory DLBCL.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Pacjent ma potwierdzonego chłoniaka rozlanego z dużych komórek B (DLBCL) lub podobny typ chłoniaka.
- •Choroba powróciła lub nie zareagowała na wcześniejsze leczenie.
- •Pacjent może był leczony wcześniej lekiem polatuzumab vedotin.
- •Choroba jest widoczna w badaniach obrazowych (np. tomografia komputerowa lub PET) i ma co najmniej jeden wymiar powyżej 1,5 cm.
- •Pacjent ma ukończone 18 lat.
- •Stan ogólny pacjenta pozwala na udział w badaniu (nie jest zbyt osłabiony).
- •Przewidywana długość życia pacjenta wynosi co najmniej 12 tygodni.
- •Wyniki badań krwi wskazują na odpowiednią liczbę białych krwinek, płytek krwi i hemoglobiny.
✗ Disqualifies
- •Pacjenci poniżej 18 roku życia są wykluczeni, ponieważ brak danych o stosowaniu tych leków u dzieci.
- •Pacjenci, których choroba bardzo szybko się rozwija lub są w bardzo złym stanie ogólnym mogą zostać wykluczeni.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 9, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (8)
City of Hope Comprehensive Cancer Center
Duarte, United States
University of California Davis Comprehensive Cancer Center
Sacramento, United States
Moffitt Cancer Center
Tampa, United States
Northwestern University
Chicago, United States
Wake Forest University Health Sciences
Winston-Salem, United States
Case Western Reserve University
Cleveland, United States
University of Oklahoma Health Sciences Center
Oklahoma City, United States
University of Virginia Cancer Center
Charlottesville, United States
Trial contact
Site Public Contact
Geoffrey Shouse
PRINCIPAL_INVESTIGATOR
Site Public Contact
Joseph M. Tuscano
PRINCIPAL_INVESTIGATOR
Site Public Contact
Bijal D. Shah
PRINCIPAL_INVESTIGATOR
Site Public Contact
Reem Karmali
PRINCIPAL_INVESTIGATOR
Site Public Contact
Rakhee Vaidya
PRINCIPAL_INVESTIGATOR
Site Public Contact
Changchun Deng
PRINCIPAL_INVESTIGATOR
Site Public Contact
Sami Ibrahimi
PRINCIPAL_INVESTIGATOR
Site Public Contact
Emily Ayers
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/8/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.